Nervgen Pharma (NGEN) Assets (2024 - 2026)

Nervgen Pharma (NGEN) posted quarterly Assets of $15.1 million for Q1 2026, down 9.02% quarter-over-quarter from $16.6 million in Q4 2025.

Nervgen Pharma (NGEN) Assets (2024 - 2026) Analysis & Trends

Nervgen Pharma (NGEN) has reported Assets for 3 consecutive years, with $15.1 million the latest figure, recorded in Q1 2026.

In Q1 2026, Assets changed N/A year-over-year to $15.1 million; the TTM figure through Mar 2026 stood at $15.1 million (changed N/A YoY), while the FY2025 annual figure was $16.6 million, up 19.31% from the prior year.
Assets slipped to $15.1 million in Q1 2026 per NGEN's latest filing, from $16.6 million in the prior quarter.
Across five years, Assets topped out at $16.6 million in Q4 2025 and bottomed at $13.9 million in Q4 2024.
Historically, Assets has averaged $15.2 million across 3 years, with a median of $15.1 million in 2026.
On a YoY basis, Assets climbed as much as 19.31% in 2025 and fell as far as 19.31% in 2025.
Nervgen Pharma's Assets stood at $13.9 million in 2024, then grew by 19.31% to $16.6 million in 2025, then fell by 9.02% to $15.1 million in 2026.
Business Quant data shows NGEN's Assets at $15.1 million in Q1 2026, $16.6 million in Q4 2025, and $13.9 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	27.42 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	41.73 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	10.03 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	10.96 Bn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	9.18 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	5.56 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	2.10 Bn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.82 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	25.60 Bn
10	Nervgen Pharma	161.78 Mn	161.78 Mn	-	65.20 Mn

Download Data